-
- Posted Wednesday June 5, 2013
TGen's Huentelman and Weiss named to 2013 Class of 40 Under 40
Newspaper recognizes TGen researchers among Phoenix's brightest young leaders
PHOENIX, Ariz. - June 5, 2013 - Dr. Matt
Huentelman of the Translational Genomics Research Institute (TGen)
and Dr. Glen Weiss of TGen and Cancer Treatment Centers of America®
(CTCA) are among the 40 business leaders under 40 years of age
named by the Phoenix Business Journal to its 13th Annual
Class of 40 Under 40.
They will be honored at an awards ceremony June 27 at the Phoenix
Art Museum.
Dr. Huentelman, Ph.D., is an Associate Professor in TGen's
Neurogenomics Division, where he oversees research programs focused
on sensory disorders, including hearing and vision loss, and on
aging and age-related diseases, such as Alzheimer's disease and the
genetics of learning and memory - highlighted recently by the
launch of TGen's MindCrowd project (www.MindCrowd.org).
Dr. Huentelman also is the Co-Director of TGen's Center for Rare
Childhood Disorders, which investigates uncommon neurologic
problems among children, often those that are only a collection of
symptoms with no diagnosis.
"I am honored to be selected among the 40 Under 40 by the Phoenix
Business Journal," Dr. Huentelman said. "This recognition serves to
highlight the significant advances that TGen has made through the
study of the human genome, and the insights and breakthroughs being
made, not only by me, but by our entire scientific staff every
day."
Dr. Weiss, M.D., is a Clinical Associate Professor in TGen's
Cancer and Cell Biology Division and is Director of Clinical
Research at CTCA®. His research focuses on genomic and other 'omics
characterizations of lung cancer, rare cancers and early-detection
strategies.
Dr. Weiss has been selected by CTCA at Western Regional Medical
Center to head the startup of a new clinical research program in
Goodyear, Ariz. Dr. Weiss is also Co-Unit Head of TGen's Lung
Cancer Research Laboratory.
"As a research scientist, being a member of the 40 Under 40 is a
reflection of the collaborations I am privileged to conduct through
TGen and CTCA," Dr. Weiss said. "As a medical doctor, these
collaborations lead to new therapies that can help the patients
that look to us for healing and hope."
The 40 Under 40 program's hundreds of alumni includes Phoenix
Mayor Greg Stanton, a member of the TGen Board of Directors, and
Arizona Diamondbacks President Derrick Hall, a member of TGen's
National Advisory Council for Pancreatic Cancer Research.
# # #
About Cancer Treatment Centers of America
Cancer Treatment Centers of America, Inc. (CTCA) is a national
network of hospitals focusing on complex and advanced stage cancer.
CTCA offers a comprehensive, fully integrated approach to cancer
treatment and serves patients from all 50 states at facilities
located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known
for delivering the Mother Standard® of care and Patient Empowerment
Medicine®, CTCA provides patients with information about cancer and
their treatment options so they can control their treatment
decisions. For more information about CTCA, go to www.cancercenter.com.
Press Contact:
Laura Malamud
Social Media Manager
623-207-2034
[email protected]
*
About TGen
Translational Genomics Research Institute (TGen) is a Phoenix,
Arizona-based non-profit organization dedicated to conducting
groundbreaking research with life changing results. TGen is focused
on helping patients with cancer, neurological disorders and
diabetes, through cutting edge translational research (the process
of rapidly moving research towards patient benefit). TGen
physicians and scientists work to unravel the genetic components of
both common and rare complex diseases in adults and children.
Working with collaborators in the scientific and medical
communities literally worldwide, TGen makes a substantial
contribution to help our patients through efficiency and
effectiveness of the translational process. For more information,
visit:www.tgen.org.
Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]
